The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The efficacy of zanubrutinib versus ibrutinib in patients with WM harboring various mutations
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Health, Monash University, Melbourne, Australia, shares some results from a genomic analysis of the ASPEN study (NCT03053440), which evaluated the efficacy of zanubrutinib versus ibrutinib in patients with Waldenström’s macroglobulinemia (WM). Results from this analysis suggest that zanubrutinib may demonstrate higher efficacy in patients with various mutations, including CXCR4 and TP53 mutations. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
